May 13, 2020
Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020
May 12, 2020
Non-Small Cell Lung Cancer (NSCLC) Market Forecasts to 2030: A Comprehensive Insight
Apr 30, 2020
Data From EMD Serono at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
Apr 28, 2020
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight
Apr 20, 2020
Genome & Company receives FDA IND clearance for GEN-001, its first anti-cancer microbiome therapeutic
Apr 09, 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Mar 13, 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Feb 11, 2020
Phosplatin Therapeutics Presents Positive Data from Two Phase I Studies in Metastatic Castrate-Resistant Prostate Cancer Patients at the 2020 Genitourinary Cancers Symposium
Nov 08, 2019
Oxford BioDynamics' EpiSwitch(TM) Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs
Nov 08, 2019
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Oct 28, 2019
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Oct 22, 2019
Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab) Over Three Years in Previously Treated Metastatic Merkel Cell Carcinoma
Sep 27, 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Sep 23, 2019
New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care
Sep 20, 2019
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
May 15, 2019
Merck KGaA, Darmstadt, Germany Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care
May 14, 2019
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Apr 12, 2019
FDA approves first targeted therapy for metastatic bladder cancer
Mar 19, 2019
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Feb 11, 2019
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma